clinical trial · NCT07252440
A Study to Evaluate the Efficacy and Safety of TTYP01 Tablets in Early Symptomatic Alzheimer's Disease
Shanghai Auzone Biological Technology Co., Ltd.·phase2·recruiting·n = 180
ADEarly Alzheimer's DiseaseTTYP01 tables 60mgTTYP01 tables 90mgTTYP01 tables 0mg
brief summary
This is a multicenter, randomized, double-blind, placebo-controlled parallel Phase II core period study to evaluate the efficacy and safety of TTYP01 Tablets in early symptomatic AD (Mild cognitive impairment \[MCI\] due to AD, or mild AD dementia). A total of 180 participants will be randomized into 3 parallel groups: 2 TTYP01 dose groups and 1 placebo group.
started
Dec 5, 2025
primary completion
Oct 23, 2028
completion
Nov 23, 2028
last updated
Nov 26, 2025
official title
A Prospective, International, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Study to Evaluate the Efficacy and Safety of TTYP01 Tablets in Early Symptomatic Alzheimer's Disease
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol